Gilgamesh Pharmaceuticals
PrivateLast Round
Series A
Mar 24, 2026
Est. Valuation
$100M
Total Funding Raised
$212.08M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Gilgamesh Pharmaceuticals is a biotechnology company that develops innovative new chemical entities for the treatment of neurological and psychiatric disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Mental Health
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gilgamesh Pharmaceuticals Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Gilgamesh Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 24, 2026 | ||||
| Corporate Funding | May 13, 2024 | ||||
| Grant | Mar 14, 2024 | ||||
| Series B | Dec 15, 2022 | ||||
| Series A | May 6, 2021 | ||||
Accelerator | Aug 24, 2020 |
Gilgamesh Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Negev Capital | Series B |
| Noetic Fund | Series A |
| Route 66 Ventures | Series A, Series B |
| Gron Ventures | Series A, Series B |
| Y Combinator | Accelerator, Seed |
| Prime Movers Lab | Series A, Series B |
| Satori Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 19, 2026
GM-3009, a novel ibogaine derivative for PTSD, is in early-stage clinical testing.
- Mar 24, 2026
$60M round completed.
Gilgamesh Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Gilgamesh Pharmaceuticals's valuation, stock price, and market status.